BMYBMY
US • —
$57.62
P/E
17.13
PEG
0.65
FCF Yield
—
Rev Growth YoY
+1.8% YoY
Gross Margin
53.7%
Health Score
5/10
D/E Ratio
2.44
Confidence
MEDIUM
Business Snapshot
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines in oncology, immunology, and cardiovascular disease. The company operates in the highly competitive pharmaceutical industry, where it maintains a strong market position driven by key products such as Eliquis and Opdivo. As a large-cap company with significant financial scale, BMY benefits from a diversified portfolio and substantial pipeline investments. The company is currently navigating a period of transition as it faces patent cliffs on several major drugs while working to bring new therapies to market.
Financial Health
Gross margin stands at 53.7%, while net margin is 12.3%, indicating the company retains a moderate portion of revenue as profit after all expenses. The balance sheet is stretched, with a debt-to-equity ratio of 2.44x, signaling high leverage relative to equity...
Risk Assessment
- DEBT/LIQUIDITY — Debt/equity of 2.44x indicates high leverage, reducing financial flexibility and increasing vulnerability to rising interest rates.
- VALUATION — P/E of 17.13x is below the sector average of 22x, which may signal market skepticism about future growth prospects rather than a genuine bargain.
- REVENUE DECELERATION — Revenue growth of just 1.8% YoY is modest and significantly trailed earnings growth of 26.3%, raising questions about the sustainability of profit expansion.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- ANALYST SENTIMENT — Only 39% of analysts rate the stock a buy, with 56% on hold, indicating limited Street conviction and potential downside risk from consensus downgrades....
Gross margin stands at 53.7%, while net margin is 12.3%, indicating the company retains a moderate portion of revenue as profit after all expenses. The balance sheet is stretched, with a debt-to-equity ratio of 2.44x, signaling high leverage relative to equity. The current ratio of 1.26x provides a modest liquidity buffer, suggesting the company can meet short-term obligations but with limited headroom. Free cash flow data is not available in this analysis, preventing a full assessment of cash generation capacity. Overall, the high debt levels and average margins suggest limited financial flexibility, which could constrain dividend growth or share repurchase programs.
- DEBT/LIQUIDITY — Debt/equity of 2.44x indicates high leverage, reducing financial flexibility and increasing vulnerability to rising interest rates. - VALUATION — P/E of 17.13x is below the sector average of 22x, which may signal market skepticism about future growth prospects rather than a genuine bargain. - REVENUE DECELERATION — Revenue growth of just 1.8% YoY is modest and significantly trailed earnings growth of 26.3%, raising questions about the sustainability of profit expansion. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - ANALYST SENTIMENT — Only 39% of analysts rate the stock a buy, with 56% on hold, indicating limited Street conviction and potential downside risk from consensus downgrades.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives